Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET.
加利福尼亞州雷德伍德市，2024年11月20日(GLOBE NEWSWIRE) -- pulmonx公司(納斯達克: LUNG) ("Pulmonx")是一家全球領先的微創治療嚴重肺部疾病的公司，今天宣佈該公司將在2024年12月4日星期三上午9:30點在紐約舉行的派傑投資第36屆年度醫療健康大會上舉行火爐邊交流。
A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at .
這次演示的現場直播和存檔網絡視頻將在Pulmonx網站的"投資者"部分提供。
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit .
pulmonx Corporation是一家全球醫療公司，是慢性阻塞性肺疾病（COPD）微創治療領域的領軍企業。Pulmonx的Zephyr內鏡瓣膜、Chartis肺功能評估系統和StratX肺部分析平台專爲最嚴重的肺氣腫/COPD患者而設計，這些患者儘管接受過醫療管理仍存在明顯的症狀。Pulmonx獲得FDA的預市場批准，用於商業化Zephyr內鏡瓣，因被認定爲「突破性設備」而入選。Zephyr內鏡瓣在全球25多個國家商業上市，被納入全球治療指南，並被廣泛認爲是改善重症肺氣腫患者的呼吸、活動和生活質量的標準護理治療方案。有關Zephyr內鏡瓣和該公司的更多信息，請訪問。
pulmonx公司(納斯達克: LUNG)是全球肺部慢性阻塞性疾病(COPD)微創治療的全球領導者。 pulmonx的Zephyr內支架瓣、Chartis肺功能評估系統、LungTraX平台和StratX肺部分析報告旨在評估和治療儘管接受醫療管理但仍然症狀嚴重的嚴重肺氣腫/COPD患者。 pulmonx獲得FDA預市場批准，開始商業化Zephyr瓣，因爲它被評定爲"突破性設備"。 Zephyr瓣已在超過25個國家商業化，被納入全球治療指南，並被普遍認爲是改善嚴重肺氣腫患者呼吸、活動和生活質量的標準療法選擇。有關Zephyr瓣和該公司的更多信息，請訪問。
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
聯繫方式
Brian Johnston
吉爾馬丁集團
investors@pulmonx.com
譯文內容由第三人軟體翻譯。
